US-based regenerative medicine developer Histogenics has filed for an initial public offering through which it aims to raise up to $65m.
Life sciences company Intrexon is set to invest $15m in the company as part of the IPO, and existing investors Sofinnova Venture Partners, Split Rock Partners and Wilmslow Estates plan to jointly buy a further $15m of shares.
Histogenics has raised $89.3m in debt and equity, according to press reports and SEC filings, including $49m in a 2012 series C round that featured BioMed Ventures, the venture capital subsidiary of life sciences realty company Biomed Realty, and BASF-backed VC fund Fintech Gimv.
However, neither are among Histogenics’ main shareholders, the largest of which is venture capital firm Sofinnova, which owns 27% of the company. Other notable shareholders include Wilmslow Estates (26.9%), Split Rock (18%), Altima Restructure Fund (6.9%) and Boston Millennia Partners (5.9%).
The proceeds will go towards advancing NeoCart, its lead product candidate, through Phase 3 clinical trials. NeoCart is an orthopaedic tissue implant to treat cartilage damage in the knee.
Cowen and Company, Needham & Company, Canaccord Genuity and BTIG are serving as underwriters for the offering.